Actym Therapeutics, Inc.
June 19, 2025
Company Presentation
Oncology
153B
Actym is a clinical-stage biotech company that has developed a platform called STACT - a novel therapeutic modality that harnesses the power of genetically modified bacterial vehicles. Our technology addresses a high unmet need to deliver large, multiplexed therapeutic payloads specifically to the disease site via a systemically administered drug. Actym Therapeutics’ lead product candidate, ACTM-838, is now generating clinical data in solid tumors, and we’re expanding our pipeline to include additional oncology and fibrotic disease assets using our modular STACT platform.
Company HQ City:
Berkeley
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2017
Lead Product in Development:
ACMT-838
CEO
Tom Smart
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
1
When you expect your next catalyst update?
Completion of Phase 1
What is your next catalyst (value inflection) update?
Dec 2026
Website
https://www.actymthera.com/
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}